-
Regeneron CEO Says Company 'Proud' Trump Received COVID-19 Antibody Treatment
Monday, October 5, 2020 - 10:59am | 409Read More...Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is "proud" to have developed an antibody treatment that was used to treat President Donald Trump, CEO Dr. Leonard Schleifer said on CNBC's "Squawk Box." What Happened: Trump's medical team recommended he take Regeneron...
-
CEOs Vs. Hedge Fund Managers: Who Gets Paid Better?
Thursday, May 26, 2016 - 10:49am | 715Read More...Do you want to become a billionaire? What about running a company? Ever wondered if you’d get richer making it to CEO or as a money manager? Well, Benzinga’s got some pointers for you. The Associated Press and Equilar, an executive data firm, recently published a list of the 10 highest-...
-
Regeneron Pharmaceuticals Loses 7% Following Q4 Miss
Tuesday, February 9, 2016 - 9:18am | 312Read More...Shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) were trading lower by around 7 percent early Tuesday morning after the company reported its fourth quarter results. Regeneron Pharmaceuticals said that it earned $2.83 per share in the fourth quarter on revenue of $1.16 billion. Wall Street...
-
Regeneron Pharmaceuticals CEO Boasts Recently Approved Cholesterol-Lowering Drug
Monday, July 27, 2015 - 4:55pm | 366Read More...Regeneron Pharmaceuticals Inc (NASDAQ: REGN)'s cholesterol-lowering drug Praluent recently received approval by the U.S. Food and Drug Administration (FDA). Leonard Schleifer, Regeneron president and CEO, was on CNBC Monday to discuss Praluent and its pricing. Non-Competitive With Statins...
-
Top Trending Tickers On StockTwits For February 11
Tuesday, February 11, 2014 - 12:10pm | 1034Read More...Here's a look at the top tickers trending on StockTwits.com Regeneron: Net profit lower, sees Eylea growth This morning, Regeneron Pharmaceuticals (NASDAQ: REGN) reported its fourth quarter results. The company announced an EPS of $2.24, beating the consensus estimate of $2.08. Revenue of $...
